The association between glucocorticoid therapy and BMI z-score changes in children with acute lymphoblastic leukemia
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
PURPOSE: Few studies have addressed the common issue of weight gain in children with acute lymphoblastic leukemia (ALL) during early phases of treatment, and even fewer have used the appropriate measure for weight fluctuation in children, BMI-for-age z-scores (BAZs). The purpose of this study is thus to measure the extent of the weight gain in BAZ during the 150 first days of treatment and to identify factors associated with the weight gain. Furthermore, we wish to raise the question of whether changes in treatment protocols automatically should be followed by an evaluation of the nutritional guidelines.
METHOD: In this retrospective study, the medical records of 51 children with ALL treated with the NOPHO ALL 2008 protocol at Copenhagen University Hospital were assessed. Patient characteristics were extracted, and height, weight, and age during the first 150 days of treatment were converted to BAZ.
RESULTS: During 150 days of treatment, the proportion of overweight/obese patients increased significantly from 9.8 to 33.3 %. The mean change in BAZ (∆BAZ) was +1 standard deviation (0.02 ± 1.16 vs. 1.12 ± 1.44; p < 0.001) Δbaz (1.26 ± 1.29 (gc) -0.04 ± 0.41; and at baz boys but compared diagnosis, during gc. girls, glucocorticoid higher in increased larger normal not obese overweight p =" 0.032).</p" patients periods significantly to treatment under vs. was weight were who with without> 0.001)>
CONCLUSION: BAZ increased significantly in children with ALL during the initial treatment with the NOPHO ALL 2008 protocol. This is likely associated with the GC administration and influenced by gender and initial BAZ.
|Tidsskrift||Supportive Care in Cancer|
|Status||Udgivet - 2015|
CURIS 2015 NEXS 145